| Date | Ref. No. | Patent No. | Title |
| 6/6/2013 | E-080-2013/0
E-080-2013/1 | | Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization |
| 5/30/2013 | E-256-2012/0 | | Novel Fusion Proteins for HIV Vaccine |
| 5/22/2013 | E-033-2013/0 | | A Novel HIV-1 Entry Inhibitor |
| 5/7/2013 | E-011-2010/0
E-266-2000/0
E-286-1988/1
E-286-1988/2 | 5,827,647
5,916,563
6,001,371
6,132,732
6,558,676 | Parvovirus B19 Vaccine |
| 4/23/2013 | E-145-2011/0 | | Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets |
| 3/21/2013 | E-074-2011/2 | | Infectious Hepatitis E Virus Genotype 3 Recombinants – Prospective Vaccine Candidates and Vector System |
| 3/18/2013 | E-043-2008/0
E-103-2010/1
E-322-2008/0 | | Human Antibodies and Fusion Proteins with Potent and Broad HIV-1 Neutralizing Activity |
| 2/26/2013 | E-168-2012/0 | | Oral Shigellosis Vaccine |
| 2/21/2013 | E-133-2012/0 | | Novel Vaccine for Prevention and Treatment of Chlamydia Infection |
| 2/16/2013 | E-214-2004/0 | 8,071,113
8,337,831 | Live Oral Shigella dysenteriae Vaccine |
| 2/15/2013 | E-127-2007/0 | | Improved Bacterial Host for Production of Anthrax Toxin Proteins and Vaccines: Bacillus anthracis BH450 |
| 2/14/2013 | E-212-2003/0 | | Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins |
| 2/14/2013 | E-283-2003/0 | | Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus) |
| 2/14/2013 | E-214-2003/0 | | Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome |
| 2/14/2013 | E-198-2003/0 | | Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12) |
| 2/5/2013 | E-004-2012/0 | | Live Attenuated Rubella Vector to Express Vaccine Antigens |
| 2/5/2013 | E-344-2003/1 | 7,758,855
8,247,225 | DNA Promoters and Anthrax Vaccines |
| 1/23/2013 | E-082-2012/0 | | Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates |
| 1/11/2013 | E-222-2012/0 | | Transmission-Blocking Malaria Vaccine |
| 1/11/2013 | E-105-2011/0 | | Typhoid-Plague Bivalent Vaccine |
| 11/21/2012 | E-132-2012/0 | | Gag-Based DNA Vaccines Against HIV |
| 9/28/2012 | E-322-2008/0 | | Method of Making a Vaccine |
| 9/12/2012 | E-042-2008/0 | | Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies |
| 8/31/2012 | E-078-2009/0 | | Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses |
| 8/17/2012 | E-222-2010/1 | | Filovirus Vaccines and Diagnostics Based on Glycoprotein-Fc Fusion Proteins |
| 7/20/2012 | E-293-2011/1 | | Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine |
| 4/30/2012 | E-011-2010/0 | | Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications |
| 4/30/2012 | E-093-2010/0 | | Diagnostic H5N1 Avian Influenza Virus Peptides |
| 3/3/2012 | E-032-2010/1 | | Bacterially Expressed Influenza Virus Recombinant HA Proteins for Vaccine and Diagnostic Applications |
| 2/21/2012 | E-271-2011/0 | | Influenza Vaccine |
| 1/18/2012 | E-188-2006/0 | | Method for Producing Significant Amounts of B19 Virus for Development of Killed or Attenuated Vaccines |
| 1/9/2012 | E-153-2006/0 | | Immunogenic Tetrasaccharide of Anthrax Spores |
| 11/1/2011 | E-053-2008/1 | | Aerosolized Vaccines |
| 10/24/2011 | E-168-2011/0 | | Vaccine to Prevent BK Polyomavirus-associated Kidney and Bladder Infections in Organ Transplant Recipients |
| 10/21/2011 | E-202-2011/1 | | Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities |
| 10/11/2011 | E-006-2011/0 | | Pertussis Vaccine |
| 9/1/2011 | E-239-2007/3 | 8,211,445 | PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus |
| 8/30/2011 | E-308-2008/0 | | A Vaccine for Shigella sonnei for Both Children and Adults |
| 7/26/2011 | E-032-2011/0 | | Multivalent Vaccines for Rabies Virus and Filoviruses |
| 3/21/2011 | E-050-2008/2
E-050-2008/3 | | Veterinary Influenza Vaccines |
| 2/28/2011 | E-049-2004/0 | 7,303,751 | Anti-Plasmodium Compositions and Methods of Use |
| 2/28/2011 | E-035-1991/0 | 6,780,417 | Transmission-Blocking Vaccine Against Malaria (1) |
| 2/28/2011 | E-090-1990/0 | 5,541,292 | Plasmodium vivax and Plasmodium knowlesi Duffy Receptor |
| 2/28/2011 | E-318-1986/0 | | Recombinant DNA Clone Containing a Genomic Fragment of PfHRP-II Gene from Plasmodium falciparum |
| 2/28/2011 | E-003-1989/0 | 5,869,608
6,384,206 | Nucleotide And Amino Acid Sequences Of The Four Variable Domains Of The Major Outer Membrane Proteins Of Chlamydia Trachomatis |
| 2/28/2011 | E-056-2005/0 | | Porcine Rotavirus Reassortant Compositions |
| 2/28/2011 | E-171-1988/1 | 6,184,024
6,676,936 | Vaccine for Dengue Virus |
| 2/28/2011 | E-139-2006/0 | 8,337,860 | Development of Dengue Virus Type 3 Vaccine Candidates |
| 2/28/2011 | E-240-2007/0 | | Development of Antigenic Chimeric St. Louis Encephalitis Virus/Dengue Virus Type Four Recombinant Viruses (SLEV/DEN4) as Vaccine Candidates for the Prevention of Disease Caused by SLEV |
| 2/28/2011 | E-159-2007/3 | 8,337,854 | Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region |
| 2/28/2011 | E-031-2006/0 | | Chlamydia Vaccine |
| 2/28/2011 | E-153-2002/0 | 8,263,091 | Method of Treating and Preventing Infections in Immunocompromised Subjects with Immunostimulatory CpG Oligonucleotides |
| 2/28/2011 | E-004-2004/2 | 20042011615
7,025,961 | Anti-Plasmodium Compositions and Methods of Use |
| 2/28/2011 | E-022-2004/0 | 7,851,194 | Live-Attenuated West Nile Virus Vaccines with Improved Immune Responses |
| 2/28/2011 | E-052-2004/0 | 7,078,507 | Vaccines Against Malarial Diseases |
| 2/28/2011 | E-067-1998/0 | 6,685,948 | Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines |
| 2/28/2011 | E-228-2000/0 | 7,524,508
8,048,427 | Subgenomic Replicons of the Flavivirus Dengue |
| 2/28/2011 | E-120-2001/0 | 7,226,602
7,560,118
8,039,003 | Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses |
| 2/28/2011 | E-357-2001/1 | | Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus |
| 2/28/2011 | E-089-2002/1 | 7,517,531
8,075,903 | Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4 |
| 2/28/2011 | E-130-2002/0
E-189-2008/2
E-285-2002/0 | 7,485,306
7,741,437 | Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection |
| 2/17/2011 | E-030-2010/0 | 8003112 | Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same |
| 1/25/2011 | E-101-2010/0 | | Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease |
| 1/4/2011 | E-317-2003/0 | 7,635,485
8,017,130 | Accelerated Vaccination Strategies to Provide Protection Against Viral Infections |
| 11/2/2010 | E-107-1998/0 | 6,562,347 | Chemokine-Tumor Antigen Fusion Proteins as Cancer Vaccines |
| 10/29/2010 | E-156-2008/0 | | Insertion of Foreign Genes in Rubella Virus and their Stable Expression in a Live, Attenuated Viral Vaccine |
| 10/25/2010 | E-266-2009/0 | | Compositions and Methods for the Treatment of Cancer |
| 9/28/2010 | E-281-1998/0 | 6,794,174 | Full-Length Infectious cDNA Clones of Tick Borne Flavivirus |
| 8/31/2010 | E-268-1997/2 | 6,749,856 | Mucosal Cytotoxic T Lymphocyte Responses |
| 7/12/2010 | E-084-2010/0 | | Novel Antigen for Use as Vaccine Against Nematode Infection |
| 6/16/2010 | E-215-2004/0 | | CpG Oligonucleotide Prodrugs |
| 6/16/2010 | E-254-2005/2 | | Improved Interleukin Expression for Immunogenic Compositions and Vaccine Adjuvant |
| 6/16/2010 | E-095-2008/0 | | A Prophylactic and Therapeutic for Preventing and Treating Tularemia by Rapid Activation of Host Cells and Antigen Recognition |
| 6/16/2010 | E-182-2008/0 | 8,222,225 | Method of Treating Pneumoconiosis with Oligodeoxynucleotides |
| 6/16/2010 | E-278-2007/0 | | Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy |
| 6/16/2010 | E-074-1999/0
E-074-1999/1
E-074-1999/2
E-074-1999/3
E-117-1995/0
E-117-1995/1
E-198-2006/0 | 5,821,081
5,843,882
5,962,653
5,962,668
5,998,587
6,015,876
6,245,737
6,420,336
6,428,790
6,586,392
6,743,577
6,780,847
6,987,096
7,048,935
7,105,169
7,339,037
7,754,420 | The Protein Cyanovirin Inactivates HIV and Influenza |
| 6/16/2010 | E-552-1982/2 | 6,998,252
7,015,024
7,045,136
7,045,313 | Recombinant Vaccines Based on Poxvirus Vectors |
| 6/16/2010 | E-217-2001/0
E-264-1997/0 | 6,685,949
7,641,906 | Moraxella Catarrhalis Lipooligosaccharide Based Conjugate Vaccines for the Prevention of Otitis Media and Respiratory Infections |
| 6/16/2010 | E-217-2001/0
E-228-1995/1 | 6,207,157
6,607,725
7,641,906 | Nontypeable Haemophilus Influenzae Lipooligosaccharide Based Conjugate Vaccines for the Prevention of Otitis Media and Respiratory Infections |
| 6/16/2010 | E-051-2002/1 | | Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor to Enhance Immune Response and Inflammation |
| 6/16/2010 | E-243-2002/1 | | Recombinant Vaccinia Viruses Expressing IL-15 and Methods of Using the Same |
| 6/16/2010 | E-344-2002/0 | 7,514,529 | Peptide Mimotope Candidates for Otitis Media Vaccine |
| 6/15/2010 | E-215-2001/0 | 7,666,674 | Use of Sterically Stabilized Cationic Liposomes to Efficiently Deliver CpG Oligonucleotides in vivo |
| 6/15/2010 | E-218-2001/0 | 7,514,414
8,227,438 | Identification of DNA Sequence Motifs that Suppress the Immune Response to CpG DNA |
| 6/14/2010 | E-198-2006/0 | | Anti-H5N1 Influenza Activity of the Antiviral Protein Cyanovirin |
| 6/14/2010 | E-158-2007/3 | 8,298,541 | Live Attenuated Virus Vaccines for La Crosse Virus and Other Bunyaviridae |
| 6/14/2010 | E-236-2007/3 | | Immunogenic Peptides Against Influenza Virus |
| 6/14/2010 | E-147-1999/0
E-147-1999/1 | 6,977,245
7,960,356
8,030,285
8,227,446
8,389,495 | Oligodeoxynucleotide and Its Use To Induce an Immune Response |
| 6/14/2010 | E-146-2008/2 | | Adoptive Immunotherapy for Reestablishing HIV-specific Cytotoxic T-cell (CD8 T-cell) Function in HIV and AIDS Patients and Methods for Assessing the Reestablishment of CD8 T-cell Function |
| 6/14/2010 | E-142-2008/0 | | Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use |
| 6/14/2010 | E-337-2001/0 | 1446158
7,368,114 | A Novel Multimeric CD4 Fusion Protein for Treating HIV Infection |
| 6/14/2010 | E-236-2003/0 | | Retrovirus-Like Particles as Vaccines and Immunogens |
| 6/10/2010 | E-012-2008/0 | | C4'-Substituted-2-Deoxyadenosine Analogs and Methods of Treating HIV |
| 6/3/2010 | E-207-2000/0 | 7,153,947 | Ixodes Salivary Anticomplement Protein |
| 6/3/2010 | E-287-2000/0 | | Cell-Free Assembly of Lentiviral Capsids |
| 5/24/2010 | E-103-2007/0 | | Therapeutic HIV Vaccine and Associated Protocols |
| 5/24/2010 | E-249-2004/1
E-308-2000/0 | | Therapeutic HIV Vaccine Vectors for Individuals Receiving Antiretroviral Therapy |
| 5/6/2010 | E-192-2008/1 | | Optimized Expression of IL-12 Cytokine Family |
| 2/12/2010 | E-279-2007/0 | 8,425,901 | Alpha 1-3 N-Acetylgalactosaminyltransferases with Altered Donor and Acceptor Specificities, Compositions, and Methods of Use: Development of Pharmaceutical Agents and Improved Vaccines |
| 2/12/2010 | E-280-2007/0 | | Beta 1,4-Galactosyltransferases with Altered Donor and Acceptor Specificities, Compositions and Methods of Use: Development of Pharmaceuticals and Improved Vaccines |
| 12/28/2009 | E-355-2001/2 | 7,494,813 | VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses |
| 10/21/2009 | E-116-2006/1
E-306-2006/4 | | Influenza Vaccines, Therapeutics, and Monoclonal Antibodies |
| 10/12/2009 | E-260-2009/0 | | Biological/Research Material for H1N1 Influenza Virus Vaccine Research |
| 10/12/2009 | E-258-2009/0 | | Biological/Research Material for HIV Vaccine Research |
| 10/7/2009 | E-328-2001/1 | 8,466,116 | Use of CpG Oligodeoxynucleotides to Induce Epithelial Cell Growth |
| 10/7/2009 | E-276-2007/1 | | Neutralization of Hepatitis C Virus (HCV) |
| 9/23/2009 | E-027-2005/0 | | Novel Chemoattractant-Based Toxins to Improve Vaccine Immune Responses for Cancer and Infectious Diseases |
| 9/21/2009 | E-299-2008/0 | | Improved Immunotherapeutic Compositions for Treatment, Diagnosis and Prevention of HIV |
| 9/3/2009 | E-169-2004/0
E-281-2005/0
E-318-2000/0 | | Rapid Diagnostic Applications of Phage |
| 8/31/2009 | E-125-2008/0 | | Monoclonal Antibodies That React With the Capsule of Bacillus anthracis |
| 7/14/2009 | E-291-2008/0 | | Membrane Proximal Region of HIV gp41 Anchored to the Lipid Layer of a Virus-Like Particle Vaccine |
| 7/14/2009 | E-249-2007/0 | 7,678,569 | A Unique Infectious Hepatitis C Virus Clone, Strain HC-TN (genotype 1a) |
| 6/8/2009 | E-341-2008/0 | | Enhanced Immune Response Against Influenza Virus by Priming with a DNA-based Vaccine |
| 6/8/2009 | E-040-2005/0 | 7,625,736 | Methods for Preparing Immunogenic Conjugates |
| 5/27/2009 | E-297-2006/0 | | CCR5-Specific Human Monoclonal Antibodies |
| 5/4/2009 | E-255-2000/0 | 7,435,801 | Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma |
| 5/4/2009 | E-296-2008/0 | 8,053,422 | Anti-Cancer Oligodeoxynucleotides |
| 3/11/2009 | E-078-2000/1 | 7,521,063
7,919,477
8,232,259 | Compounds Used to Improve Human Immune Responses in Diseases such as Allergies, Infections, and Cancer |
| 2/17/2009 | E-173-2008/0 | | Compositions and Methods for Vaccine and Virus Production |
| 2/2/2009 | E-289-2007/0
E-289-2007/1 | | Sialostatin Mediation Controls Blood-feeding Success of the Tick Ixodes scapularis |
| 12/1/2008 | E-029-2007/0 | | A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics |
| 11/1/2008 | E-123-2005/1 | | HIV gp41-Membrane Proximal External Region Arrayed on Hepatitis B Surface Antigen Particles for HIV Diagnostic and Vaccine Applications |
| 10/1/2008 | E-301-2003/0 | 8,048,432 | A Method with Increased Yield for Production of Polysaccharide-Protein Conjugate Vaccines Using Hydrazide Chemistry |
| 10/1/2008 | E-085-2005/0 | 8,173,135 | Methods for Preparing Complex Multivalent Immunogenic Conjugates |
| 10/1/2008 | E-183-2005/0 | | Methods for Conjugation of Oligosaccharides or Polysaccharides to Protein Carriers Through Oxime Linkages Via 3-Deoxy-D-Manno-Octulsonic Acid |
| 10/1/2008 | E-145-2004/3 | 7,914,788
8,404,818 | Monoclonal Antibodies Against Orthopoxviruses |
| 10/1/2008 | E-152-2004/0 | | Use of Suppressive Oligonucleotides to Treat Uveitis |
| 10/1/2008 | E-183-2002/0 | 8,043,622 | Method of Treating Infectious and Inflammatory Lung Disease with Suppressive Oligonucleotides |
| 10/1/2008 | E-210-2001/0 | 7,541,043
8,071,084
8,337,832 | Vaccine for Protection Against Shigella sonnei Disease |
| 9/1/2008 | E-123-2007/0
E-146-2004/0 | 8,071,100 | Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF) |
| 9/1/2008 | E-268-2002/0 | 7,261,900
8,394,387 | Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines |
| 9/1/2008 | E-189-2007/0 | | Monodisperse and Modified Yersinia pestis Capsular F1-V Antigen Fusion Proteins for Vaccination Against Bubonic and Pneumonic Plague |
| 9/1/2008 | E-225-2000/0 | 10-0899030
1294858
153530
2001268709
266418
6,923,971
7,662,397
7,744,902 | Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation |
| 9/1/2008 | E-178-1999/0
E-178-1999/1
E-178-1999/2 | 00810119.1
1287152
147447
7,820,182
7,829,102
7,842,798
784216 | Human-Bovine Chimeric Respiratory Syncytial Virus (RSV) Vaccines |
| 9/1/2008 | E-032-2008/0 | | Use of Saccharides Cross-Reactive with Bacillus anthracis Spore Glycoprotein as a Vaccine Against Anthrax |
| 9/1/2008 | E-023-2002/0 | 7,763,451
8,044,189 | Methods for Preparing Bacillus anthracis Protective Antigen for Use in Vaccines |
| 9/1/2008 | E-343-2002/0 | 7,803,386 | gammaPGA Conjugates for Eliciting Immune Responses Directed Against Bacillus anthracis and Other Bacilli |
| 8/1/2008 | E-141-2003/0 | 7,993,647 | Monoclonal Antibodies to HIV-1 Vpr |
| 6/1/2008 | E-298-2007/0 | | Immunostimulatory Combinations of TLR Ligands and Methods of Use |
| 4/1/2008 | E-326-2006/1 | | Codon Optimized Genes for Subunit Vaccines |
| 4/1/2008 | E-077-2008/0 | | HPV Virus-Like Particles for Delivery of Gene-Based Vaccines |
| 4/1/2008 | E-036-2005/0 | 7,892,569 | Identification of a Cell-Surface Co-Receptor that Mediates the Uptake and Immunostimulatory Activity of “D” Type CpG Oligonucleotides |
| 4/1/2008 | E-212-2001/0 | 7,311,916 | Polypeptides for Eliciting Neutralizing Antibodies Against HIV |
| 3/1/2008 | E-316-2003/0 | | Immunoglobulins with Potent and Broad Antiviral (HIV) Activity Based on scFv Joined by Flexible Linker to Fc |
| 1/1/2008 | E-105-1996/1 | 6,099,847 | Chimeric Gag Pseudovirions |
| 1/1/2008 | E-020-1999/0 | 6,797,275
7,754,227
8,202,520 | A Method of Immunizing Humans Against Salmonella typhi Using a Vi-rEPA Conjugate Vaccine |
| 12/1/2007 | E-241-2001/1 | 7,094,598 | Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag |
| 10/1/2007 | E-072-2004/3
E-072-2004/4 | | An HIV Protein for Use as a Novel Therapeutic or Vaccine Component |
| 10/1/2007 | E-263-2005/0 | 8,252,550 | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
| 10/1/2007 | E-039-2002/0 | | Potent HIV-1 Entry Inhibitors and Immunogens |
| 8/1/2007 | E-248-2006/0
E-248-2006/1 | | A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes |
| 6/1/2007 | E-241-2001/0
E-241-2001/1
E-267-2004/1 | 7,094,598
7,635,688
8106026
8106027
8124592 | Increased Protein Expression Vector for Vaccine Applications |
| 6/1/2007 | E-300-2002/0 | | Development of a Novel High Throughput Assay to Measure Cell-Infection with Vaccinia Strains Expressing Reporter Genes |
| 6/1/2007 | E-274-2000/0 | 7,527,797 | Vibrio cholerae O139 Conjugate Vaccines |
| 5/1/2007 | E-043-2006/3 | | Enhanced, Targeted Delivery for DNA Vaccines |
| 5/1/2007 | E-158-1998/0 | 6,858,211
7,247,307
7,553,490
8,168,195 | Vaccine Against Eschericha coli 0157 Infection, Composed of Detoxified LPS Conjugated to Proteins |
| 4/1/2007 | E-017-2001/0 | | Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment and Prevention of Hepatitis C |
| 4/1/2007 | E-043-2000/0 | 6,930,176
7,148,323 | Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination |
| 3/1/2007 | E-218-2004/0
E-280-2006/1
E-324-2005/3 | 8,044,185
8,268,323
8147840 | Novel System for HIV-1 Vaccine Development |
| 12/1/2006 | E-174-2004/0
E-174-2004/1
E-174-2004/2 | | Modified Bacterial Strain for Otitis Media Vaccine |
| 12/1/2006 | E-173-2005/0 | | Noncovalent HIV Env-CD4 Complexes as HIV Vaccines |
| 12/1/2006 | E-311-2006/1 | | Chitosan as a Universal Vaccine Adjuvant, Antigen Depot and Cytokine Depot |
| 11/1/2006 | E-159-1999/0 | 7,101,558 | Vaccine Production Strain for Acellular Pertussis Vaccine |
| 9/1/2006 | E-203-1997/0 | 6,432,408 | Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E |
| 8/1/2006 | E-128-2000/0 | | Methods and Compositions for the Production of Highly Effective Vaccines Against Cancers and Infectious Diseases |
| 5/1/2006 | E-055-1999/0 | 6,680,176 | Identification of Candidate Ligands which Modulate Antigen Presenting Cells |
| 5/1/2006 | E-267-2005/0 | 7,833,754 | Increased Cytokine Expression |
| 2/1/2006 | E-152-1991/1 | 5,932,218
6,214,347
6,294,322
7,094,405 | Multideterminant Peptides That Elicit Helper T-Lymphocyte Cytotoxic T-Lymphocyte and Neutralizing Antibody Responses Against HIV-1 |
| 12/1/2005 | E-151-2004/0 | | Efficient Growth of Wild-Type Hepatitis A Virus in Cell Culture for Development of Live Vaccines |
| 11/1/2005 | E-143-1998/0 | 1 080 201
1080201
6,919,442
EP 1 080 301 | A Novel Post-Transcriptional Regulatory Element (PRE) and Its Use in Expression Cassettes and Recombinant Viruses |
| 9/1/2005 | E-092-2002/0
E-295-2004/0 | 7,820,181
7,919,301
8,367,074 | Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines |
| 8/1/2005 | E-337-2004/0 | | Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development |
| 8/1/2005 | E-155-2005/0
E-155-2005/1
E-155-2005/2
E-155-2005/3 | 7,691,579 | Immunogenic Peptides From Human Papillomavirus Type 16 E2 |
| 8/1/2005 | E-302-2004/0 | | A32 Monoclonal Antibody Fusion Protein for Use as HIV Inhibitors and Vaccines |
| 8/1/2005 | E-075-2001/0 | | Methods and Compositions for Production and Purification of Recombinant Staphylococcal Enterotoxin B (rSEB) |
| 4/1/2005 | E-267-2004/0
E-267-2004/1 | | Candidate DNA HIV Vaccine |
| 4/1/2005 | E-176-2003/0 | | Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria |
| 4/1/2005 | E-023-2003/0 | 7,303,754 | MVA Expressing Modified HIV envelope, gag, and pol Genes |
| 3/1/2005 | E-251-2004/0 | | Broadly Cross-Reactive HIV-1 Neutralizing Human Monoclonal Antibodies |
| 12/1/2004 | E-004-2005/0
E-004-2005/4 | 7,988,971 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses |
| 12/1/2004 | E-299-2004/0 | | Vaccines Against Crimean-Congo Hemorrhagic Fever |
| 11/1/2004 | E-178-2004/0 | 7,598,071 | Infectious Clone of Human Parvovirus B19 and Methods of Use |
| 6/1/2004 | E-228-2003/1
E-228-2003/2 | | Soluble SARS Coronavirus Spike Protein (S Protein) |
| 4/1/2004 | E-073-2004/0 | | Reduction of HIV-1 Replication by a Mutant Apolipoprotein B mRNA Editing Enzyme-Catalytic Polypeptide-like 3G (APOBEC3G) |
| 1/1/2004 | E-324-2003/0 | | Streptococcus Lipoprotein Antigens |
| 12/1/2003 | E-019-2004/0 | | Construction of Replication-Competent Chimeric Simian Immunodeficiency Virus (SIV) Human Immunodeficiency Virus Type 1 (HIV-1) Viruses that Replicate Using HIV-1 Reverse Transcriptase and Integrase (IN): A Model System for Development and Testing of Antiviral Agents for the Treatment of HIV-1 Infection |
| 11/1/2003 | E-044-2003/0 | 7,731,971 | Enhanced HIV-1 Vaccine Cytotoxic T Cell Epitope from Conserved Region of HIV-1 Reverse Transcriptase |
| 9/1/2003 | E-150-1994/0 | 5,622,861 | Hepatitis A Virus Receptor And Methods Of Use |
| 1/1/2003 | E-144-2002/0
E-144-2002/1 | 7,566,451
7,803,913
8,110,192 | vel Broadly Cross-Reactive HIV Neutralizing Human Monoclonal Antibodies Selected from Fab Phage Display Libraries Using a Novel Strategy Based on Alternative Antigen Panning
and
Novel Broadly Cross-Reactive HIV-1 Neutralizing Human Single-Chain Antibodies Derived from X5 by DNA Shuffling and Alternating Antigen Panning |
| 10/1/2002 | E-100-1999/0 | 7,084,266 | Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof |
| 10/1/2002 | E-102-1999/0 | 7,009,044 | HCV/BVDV Chimeric Genomes and Uses Thereof |
| 10/1/2002 | E-173-1999/0 | 7,129,342 | Infectious cDNA Clone of GB Virus B and Uses Thereof |
| 10/1/2002 | E-356-2001/0 | 7,282,205
7,635,476 | Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus |
| 5/1/2002 | E-246-2001/0 | 6,852,324 | Immunization for Ebola Virus Infection |
| 3/1/2002 | E-328-2001/0 | 7,615,227
7,935,351 | Use of CpG Oligodeoxynucleotides to Encourage Angiogenesis |
| 2/1/2002 | E-282-2001/0 | | N-Formyl Peptide Receptor Mediation of Platelet Chemotaxis Toward Injured Cells and Activation of Immune Response |
| 2/1/2002 | E-241-2001/0 | 7,635,688
8106026
8106027
8124592 | Vaccination Strategies to Provide Protection Against the Ebola Virus |
| 2/1/2002 | E-214-2001/0 | 7,354,909
7,959,934 | Novel Method for Rapidly Generating Mature Dendritic Cells from Peripheral Blood Monocytes and Myeloid Precursors |
| 2/1/2002 | E-122-2001/0 | 7,388,089
7,964,576
8,343,499 | Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof |
| 1/1/2002 | E-126-2000/0 | 6,673,905
7,211,445 | A Method for Bioconjugation Using Diels-Alder Cycloaddition |
| 1/1/2002 | E-285-2000/0 | | LL-37 is an Immunostimulant |
| 1/1/2002 | E-278-2001/0 | | Two cDNA Clones of Hepatitis E Virus (HEV) that are Infectious for Primates and Encode a Virulent and an Attenuated Virus Respectively |
| 1/1/2002 | E-089-2001/0 | 7,968,298 | Suppression of CCR5- but not CXCR4-Tropic HIV-1 Replication in Lymphoid Tissue by Human Herpes Virus 6 |
| 1/1/2002 | E-126-2001/0 | 7,189,513
7,507,538 | Human Papilloma Virus Immunoreactive Peptides |
| 11/1/2001 | E-304-1998/0 | | Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications |
| 6/1/2001 | E-008-1998/0 | | Beta2-Microglobulin Fusion Proteins And High Affinity Variants |
| 2/1/2001 | E-275-2000/0
E-275-2000/1
E-275-2000/2
E-275-2000/3 | 7,470,430 | Modifications of HIV Env, Gag and Pol Enhance Immunogenicity for Genetic Immunization |
| 12/1/2000 | E-208-2000/0 | 7,078,508 | Ixodes scapularis Tissue Factor Pathway Inhibitor |
| 4/1/2000 | E-078-1999/0 | 6,531,131 | Conjugate Vaccine for Neisseria Meningitidis |
| 4/1/2000 | E-200-1993/0
E-200-1993/1 | 6,039,957
6,171,596 | Oligomeric HIV-1 Envelope Glycoproteins |
| 4/1/2000 | E-148-1998/0
E-148-1998/1 | 6,656,706
7,608,422
8,076,100 | Molecular Clones with Mutated HIV GAG/POL and SIV Genes |
| 9/1/1999 | E-070-1999/2 | 6,911,527 | Novel HIV Related Peptides |
| 2/1/1999 | E-217-1998/0 | 6,719,978
7,371,572
7,479,280
7,875,450 | Chimeric Virus-Like Particles For The Induction Of Autoantibodies |
| 9/1/1998 | E-141-1992/2 | | Recombinant Proteins Of A Pakistani Strain Of Hepatitis E And Their Use In Diagnostic Methods And Vaccines |
| 7/1/1998 | E-276-1988/1 | 5,674,720 | Design And Construction Of Non-Infectious Human Retroviral Mutants Deficient In Genomic RNA |
| 7/1/1998 | E-086-1991/0 | | Lipopolysaccharide Carriers For Use In Vaccines |
| 4/1/1996 | E-454-1986/3 | 5,604,093
6,018,027
6,054,283
RE38824 | Human B Lymphotropic Virus (HBLV) Isolation And Products |
| 5/1/1995 | E-032-1994/0 | 5,882,852
7,070,790 | Nucleotide And Deduced Amino Acid Sequences Of The Envelope-1 And Core Genes Of Isolates Of Hepatitis C Virus And Methods Of Use |
| 2/1/1995 | E-202-1994/0 | 5,738,855 | Synthesis of Typhoid Fever Vaccine from a Plant or Fruit Polysaccharide |
| 11/1/1994 | E-325-1983/2 | | Production Of Complementary DNA Representing Hepatitis A Viral Sequences By Recombinant DNA Methods And Uses Therefor |